	US 12,064,479 B2
	Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
Daryl C. Drummond, Lincoln, MA (US); Dmitri B. Kirpotin, San Francisco, CA (US); Mark E. Hayes, Mill Valley, CA (US); Alexander Koshkaryev, Norwood, MA (US); and Ross B. Fulton, Southborough, MA (US)
Assigned to Akagera Medicines, Inc., Boxford, MA (US)
Filed by Akagera Medicines, Inc., Boxford, MA (US)
Filed on May 25, 2023, as Appl. No. 18/324,097.
Claims priority of provisional application 63/346,197, filed on May 26, 2022.
Claims priority of provisional application 63/345,823, filed on May 25, 2022.
Prior Publication US 2023/0381303 A1, Nov. 30, 2023
Int. Cl. A61K 39/395 (2006.01); A61K 39/215 (2006.01); A61K 39/385 (2006.01); A61K 47/24 (2006.01); A61K 47/28 (2006.01); A61K 47/69 (2017.01)

CPC A61K 39/385 (2013.01) [A61K 39/215 (2013.01); A61K 47/24 (2013.01); A61K 47/28 (2013.01); A61K 47/6929 (2017.08); A61K 47/6935 (2017.08)]

28 Claims

1. A nucleic acid lipid nanoparticle (LNP) composition comprising:

a. a nucleic acid;

b. an ionizable cationic lipid at a N/P ratio of 3 to 8 relative to the nucleic acid in a total amount of 40-65 mol % of the total lipid content of the LNP composition;

c. a sterol in a total amount of 25-45 mol % of the total lipid content of the LNP composition;

d. one or more phospholipids in a total amount of phospholipids of 5-25 mol % of the total lipid content of the LNP composition, and comprising a phosphatidyl-L-serine lipid in a total amount of 2.5-10 mol % of the total lipid content of the LNP composition; and

e. a conjugated lipid in a total amount of 0.5-2.5 mol % of the total lipid content of the LNP composition.